Review of: "Design and Molecular Screening of Various Compounds by Molecular Docking as BACE-1 Inhibitors"

Samuel Silva da Rocha Pita Silva da Rocha Pita

Potential competing interests: No potential competing interests to declare.

Since Alzheimer's disease (AD) still does not have its “magic bullet” (like Paul Ehrlich enounced), many studies have been developed to explore some AD targets. One of these targets is Beta Secretase Amyloid Cleaving Enzyme (BACE-1), which has been studied by plenty of research groups employing many compounds. From natural products, I could mention the flavonoid family that was in silico tested against BACE-1 in the following articles:

https://pubmed.ncbi.nlm.nih.gov/18295609/

https://pubmed.ncbi.nlm.nih.gov/20598535/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471523/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023116/

https://pubmed.ncbi.nlm.nih.gov/31618777/

https://link.springer.com/article/10.1007/s11030-023-10726-3

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941774/

Since the articles below range from 2008 to 2024, after reading the manuscript entitled “Design and Molecular Screening of Various Compounds by Molecular Docking as BACE-1 Inhibitors,” I did not find some innovative approaches that could justify this publication in this journal. Then, my personal opinion is to reject this submission in its present form.